China Sky One Medical, Inc. - Financial and Strategic Analysis Review
Summary
Global Markets Direct’s “China Sky One Medical, Inc. - Financial and Strategic Analysis Review” is an in-depth business, strategic and financial ...
Summary
Global Markets Direct’s “China Sky One Medical, Inc. - Financial and Strategic Analysis Review” is an in-depth business, strategic and financial analysis of China Sky One Medical, Inc. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis of the company. This highlights its strengths and weaknesses and the opportunities and threats it faces going forward.
China Sky One Medical, Inc. (CSKI) is principally focused on the development, manufacture, and marketing of over the counter plant and herb based medicinal and pharmaceutical products. The company’s chief product portfolio includes external use Traditional Chinese Herbal Remedies/Medicines (TCM). Its products are sold in the market under the brand names TDR, Kangxi, Elisa and Slim Patch. CSKI has its sales and marketing network spread across the globe. It is headquartered Harbin, China. In 2009, the company obtained SFDA production approval for Calcium Folinate Injection and Policresulen vaginal suppositories.
Recent Developments
Aug 06, 2009: China Sky Appoints William Wei Lee As Independent Director
Aug 14, 2009: China Sky Reports Net Income Of $9.5 Million In Q2 2009
Sep 03, 2009: China Sky One Medical Submits Application To Perform Clinical Trial To SFDA
Scope
Summary
Global Markets Direct’s “China Sky One Medical, Inc. - Financial and Strategic Analysis Review” is an in-depth business, strategic and financial ...
 Format : Download: PDF Author : Global Markets Direct Number of Pages : 40 Publisher : MarketResearch.com List Price: Our Price: $125.00 |
Product Description
China Sky One Medical, Inc. - Financial and Strategic Analysis ReviewSummary
Global Markets Direct’s “China Sky One Medical, Inc. - Financial and Strategic Analysis Review” is an in-depth business, strategic and financial analysis of China Sky One Medical, Inc. The report provides a comprehensive insight into the company, including business structure and operations, executive biographies and key competitors. The hallmark of the report is the detailed strategic analysis of the company. This highlights its strengths and weaknesses and the opportunities and threats it faces going forward.
China Sky One Medical, Inc. (CSKI) is principally focused on the development, manufacture, and marketing of over the counter plant and herb based medicinal and pharmaceutical products. The company’s chief product portfolio includes external use Traditional Chinese Herbal Remedies/Medicines (TCM). Its products are sold in the market under the brand names TDR, Kangxi, Elisa and Slim Patch. CSKI has its sales and marketing network spread across the globe. It is headquartered Harbin, China. In 2009, the company obtained SFDA production approval for Calcium Folinate Injection and Policresulen vaginal suppositories.
Recent Developments
Aug 06, 2009: China Sky Appoints William Wei Lee As Independent Director
Aug 14, 2009: China Sky Reports Net Income Of $9.5 Million In Q2 2009
Sep 03, 2009: China Sky One Medical Submits Application To Perform Clinical Trial To SFDA
Scope
- Provides key company information for business intelligence needs
- The company’s strengths and weaknesses and areas of development or decline are analyzed. Financial, strategic and operational factors are considered.
- The opportunities open to the company are considered and its growth potential assessed. Competitive or technological threats are highlighted.
- The report contains critical company information - business structure and operations, the company history, major products and services, key competitors, key employees and executive biographies, different locations and important subsidiaries.
- The report provides detailed financial ratios for the past five years as well as interim ratios for the last four quarters.
- Financial ratios include profitability, margins and returns, liquidity and leverage, financial position and efficiency ratios.
- A quick “one-stop-shop” to understand the company.
- Enhance business/sales activities by understanding customers’ businesses better.
- Get detailed information and financial & strategic analysis on companies operating in your industry.
- Identify prospective partners and suppliers - with key data on their businesses and locations.
- Capitalize on competitors’ weaknesses and target the market opportunities available to them.
- Compare your company’s financial trends with those of your peers / competitors.
- Scout for potential acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.